The FDA has approved Blenrep with BVd as a third-line treatment for relapsed or refractory multiple myeloma.

Multiple myeloma survivor Ronald D. Chin, one of CURE’s contributing bloggers, shared a bit of his blood cancer journey in a ...

Black survivors of multiple myeloma say the latest developments in treatment give them hope even as federal research cuts ...

In the late-stage MajesTEC-3 trial, Tecvayli plus the subcutaneous formulation of J&J’s antibody drug Darzalex beat ...

The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.

TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Kenneth C. Anderson, MD, a globally recognized ...

DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free survival in 3L+ indicated population ...

You don’t expect to break a rib while doing light housekeeping. Similarly, you wouldn’t think your worsening back pain might be caused by a type of blood cancer. However, these are among classic ...

BeOne Medicines (($ONC)) announced an update on their ongoing clinical study. BeOne Medicines (ONC) is currently conducting a Phase 1b/2 clinical ...

The University of California, Irvine has licensed a new cancer-fighting immunotherapy to biotech firm GlyTR Therapeutics Inc. for commercialization, paving the way for what researchers call a ...

Drs Joseph Mikhael and Peter Voorhees discuss considerations for treating smoldering multiple myeloma, including recent ...

Treatment for multiple myeloma has evolved significantly, with long-term survival increasingly within reach for many patients. Achieving optimal outcomes requires not only addressing symptoms but also ...